A list of lifesaving drugs and medicines will get cheaper from Monday, 22 September 2025, after the rate cuts under the new ...

As per the new GST structure, the earlier structure of four tax slabs (5%, 12%, 18%, 28%) has been simplified into two tax slabs (5% and 18%). Additionally, a new 40% slab was introduced for ‘luxury’ ...

GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society Congress 2025: London, UK Wednesday, September 17, 2025, 11:00 Hrs [IST] GSK ...

GST Rate Cut on Cancer Drugs: Medical expenses especially for cancer patients and those struggling with chronic illnesses are set to go down as GST 2.0 is rolled out with effect from 22 September 2025 ...

The evaluation committee considered evidence submitted by AstraZeneca, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...

A news anchor who had just recently started a new job at a Mississippi-based TV news station died suddenly of a heart attack. Celeste Wilson was only 42 years old, according to the "Today" show. "We ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

Mepolizumab is the only approved biologic evaluated in patients with an eosinophilic phenotype characterized by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. 1,2 BEC is captured by ...

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive ...

1. In this randomized controlled trial, mepolizumab decreased the annualized rate of moderate or severe exacerbations when added to triple therapy in patients with eosinophilic chronic obstructive ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

In patients with COPD, eosinophilic inflammation leads to exacerbations, with increased use of health care resources and mortality. New research findings with mepolizumab treatment are summarized in a ...